41. Yan BS, Pichugin AV, Jobe O, Helming L, Eruslanov EB, et al. (2007) Progression of pulmonary tuberculosis and efficiency of bacillus Calmette- Guerin vaccination are genetically controlled via a common sst1-mediated mechanism of innate immunity. J Immunol 179: 6919–6932. 42. Sissons J, Yan BS, Pichugin AV, Kirby A, Daly MJ, et al. (2009) Multigenic control of tuberculosis resistance: analysis of a QTL on mouse chromosome 7 and its synergism with sst1. Genes Immun 10: 37–46. 43. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM (2003) Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 47: 783–785. 44. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, et al. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49: 2294–2301. 45. Hoff DR, Caraway ML, Brooks EJ, Driver ER, Ryan GJ, et al. (2008) Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 52: 4137–4140. 46. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178: 2249. 47. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, et al. (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178: 2243–2247. 48. Pearl JE, Saunders B, Ehlers S, Orme IM, Cooper AM (2001) Inflammation and lymphocyte activation during mycobacterial infection in the interferon-c- deficient mouse. Cellular Immunology 211: 43–50. 49. Turner OC, Basaraba RJ, Frank AA, Orme IM in Granulomatous Infections and Inflammation: Cellular and Molecular Mechanisms D. L. Boros, Ed. (ASM Press, Washington, DC, 2003). pp 65–84. 50. Johnson CM, Pandey R, Sharma S, Khuller GK, Basaraba RJ, et al. (2005) Oral therapy using nanoparticle encapsulated anti-tuberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother. 51. McMurray DN (2003) Hematogenous reseeding of the lung in low-dose, aerosol- infected guinea pigs: unique features of the host-pathogen interface in secondary tubercles. Tuberculosis (Edinb) 83: 131–134. 52. Basaraba RJ, Smith EE, Shanley CA, Orme IM (2006) Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol. Infect Immun 74: 5397–5401. 53. Ordway DJ, Shanley CA, Caraway ML, Orme EA, Bucy DS, et al. (2010) Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrobial Agents & Chemotherapy 54: 1820–1833. 54. Orme IM (2003) The mouse as a useful model of tuberculosis. Tuberculosis (Edinb) 83: 112–115. 55. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, et al. (2004) Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tubercu- losis. Antimicrob Agents Chemother 48: 2951–2957. 56. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, et al. (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47: 2118–2124. 57. Nikonenko BV, Sacksteder KA, Hundert S, Einck L, Nacy CA (2008) Preclinical study of new TB drugs and drug combinations in mouse models. Recent Patents Anti-Infect Drug Disc 3: 102–116. 58. Arriaga AK, Orozco EH, Aguilar LD, Rook GAW, Pando RH (2002) Immunological and pathological comparative anaylsis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 128: 229–237. 59. McMurray DN (2001) Disease model: pulmonary tuberculosis. Trends Mol Med 7: 135–137. 60. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962–966. 61. Ahmad Z, Klinkenberg LG, Pinn ML, Fraig MM, Peloquin CA, et al. (2009) Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug- resistant, Mycobacterium tuberculosis in the guinea pig. Journal of Infectious Diseases 200: 1136–1143. 62. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, et al. (2005) Ipr1 gene mediates innate immunity to tuberculosis. Nature 434: 767–772. 63. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, et al. (2009) Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission Visualization of M. tuberculosis in Animal Models tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrobial Agents & Chemotherapy 53: 4879–4884. 64. Gil O, D´ıaz I, Vilaplana C, Tapia G, D´ıaz J, et al. (2010) Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS ONE 5: e10030. 65. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F (2009) Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 10: 943–948. 66. Cardona PJ (2007) New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets 6: 27–39. 67. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, et al. (2008) Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 4: e1000204. 68. Wayne LG, Hayes LG (1996) An in vitro model for sequential study of shiftdown of mycobacterium tuberculosis through two stages of nonreplicating persistence. infect immun 64: 2062–2069. 69. Ly LH, Russell MI, McMurray DN (2008) Cytokine profiles in primary and secondary pulmonary granulomas of Guinea pigs with tuberculosis. Am J Respir Cell Mol Biol 38: 455–462. 70. OjhaAea (2008) Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harboring drug tolerant bacteria. Molecular Microbiology;In Press. 71. Ca´ceres N, Tapia G, Ojanguren I, Altare F, Gil O, Pinto S, et al. (2009) Evolution of foamy macrophages in the pulmonary granulomas of experimental tuberculosis models. Tuberculosis 89: 175–182. 72. Cardona P (2009) A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 37: 80–86. 73. Smith DW, Balasubramanian V, Wiegeshaus E (1991) A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemo- therapy: the effect on bacilli in the initial phase of treatment. Tubercle 72: 223–231. 74. Hanscheid T, Ribeiro CM, Shapiro HM, Perlmutter NG (2007) Fluorescence microscopy for tuberculosis diagnosis. Lancet Infect Dis 7: 236–237. 75. Kojima K, Niri M, Setoguchi K, Tsuda I, Tatsumi N (1989) An automated optoelectronic reticulocyte counter. Am J Clin Pathol 92: 57–61. 76. Oster G (1951) [Fluorescence of auramine O in the presence of nucleic acid.]. C R Hebd Seances Acad Sci 232: 1708–1710. 77. Seiler P, Ulrichs T, Bandermann S, Pradl L, Jorg S, et al. (2003) Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis 188: 1326–1331. 78. Ulrichs T, Lefmann M, Reich M, Morawietz L, Roth A, et al. (2005) Modified immunohistological staining allows detection of Ziehl-Neelsen-negative Myco- bacterium tuberculosis organisms and their precise localization in human tissue. J Pathol 205: 633–640. 79. Ulrichs T, Kaufmann SH (2006) New insights into the function of granulomas in human tuberculosis. J Pathol 208: 261–269. 80. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, et al. (2005) Weekly Moxifloxacin and Rifapentine is More Active than the Denver Regimen in Murine Tuberculosis. Am J Respir Crit Care Med. 81. Nuermberger EL, Yoshimatsu T, Tyagi S, O’Brien RJ, Vernon AN, et al. (2004) Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169: 421–426. 82. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, et al. (2009) A replication clock for Mycobacterium tuberculosis. Nat Med 15: 211–214. 83. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, et al. (2009) Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary tuberculosis. Chest 137: 122–128. 84. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, et al. (2004) The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72: 6622–6632. 85. Brooks JV, Orme IM (1998) Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. Antimicrob Agents Chemother 42: 3047–3048. 86. Kraft SL, Dailey D, Kovach M, Stasiak KL, Bennett J, et al. (2004) Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect Immun 72: 5963–5971. PLoS ONE | www.plosone.org 14 March 2011 | Volume 6 | Issue 3 | e17550